The SPATA13 Polyclonal Antibody (PAC01508) is a valuable tool for researchers studying SPATA13, a protein involved in sperm development and male fertility. This antibody, generated in rabbits, shows high reactivity with human samples and has been validated for use in Western blot applications. By specifically binding to SPATA13, this antibody enables the detection and analysis of the protein in various cell types, making it ideal for studies in reproductive biology and infertility research.SPATA13, also known as spermatogenesis-associated protein 13, is essential for the proper development and function of sperm cells.
Mutations in the SPATA13 gene have been linked to male infertility and impaired sperm production, highlighting the importance of this protein in reproductive health. By studying SPATA13, researchers can gain valuable insights into the mechanisms underlying male fertility and potentially develop new treatments for infertility disorders.The SPATA13 Polyclonal Antibody is a powerful tool for investigating the role of SPATA13 in sperm development and male fertility, offering new opportunities for advancements in reproductive biology and infertility research.
The image on the left is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using PACO15058(SPATA13 Antibody) at dilution 1/25, on the right is treated with fusion protein. (Original magnification: x200).
Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Hela cells, Primary antibody: PACO15058(SPATA13 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes.
The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using PACO15058(SPATA13 Antibody) at dilution 1/25, on the right is treated with fusion protein. (Original magnification: x200).
Background:
Acts as guanine nucleotide exchange factor (GEF) for RHOA, RAC1 and CDC42 GTPases. Regulates cell migration and adhesion assembly and disassembly through a RAC1, PI3K, RHOA and AKT1-dependent mechanism. Increases both RAC1 and CDC42 activity, but decreases the amount of active RHOA. Required for MMP9 up-regulation via the JNK signaling pathway in colorectal tumor cells. Involved in tumor angiogenesis and may play a role in intestinal adenoma formation and tumor progression. Both the ABR and the SH3 domains contribute to maintaining the protein in an inhibited conformation by associating with the C-terminal tail. Binding of these domains to the C-terminal tail inhibits the activity of the protein by blocking a region that is required for its GEF activity.
